Zhonghua Zhong Liu Za Zhi. 2024 Apr 29;46:517-525. doi: 10.3760/cma.j.cn112152-20240111-00022.
Bone-modifying agents are a class of drugs that alleviate a series of bone-related events such as pain, pathologic fracture, spinal cord compression, and hypercalcemia caused by bone metastases, and currently include bisphosphonates and RANKL inhibitors. Due to the widespread use of bone-modifying agents, the adverse effects of them are gradually increasing and affecting patients' quality of life. The Breast Cancer Group, Chinese Medical Doctor Association, and the International Medical Society, Chinese Anti-cancer Association have organized relevant experts to focus on the treatment of bone metastases of advanced malignant tumors based on evidence-based medicine, discuss the management of adverse reactions to bone-modifying agents and form the consensus. Based on the first Expert Consensus on Safety Management of Bone-modifying Agents in China, this consensus added the definition of osteonecrosis of the jaw related to bone-modifying agents, the occurrence of adverse reactions of bone-modifying drugs reported in the literature, and summarized the clinical experience of clinicians in the management of adverse reactions in practice in recent years, and ultimately, the expert group members discussed and proposed reasonable suggestions to guide clinicians in the safety management of bone-modifying agents.
骨改良药物是一类能缓解由骨转移引起的一系列与骨相关事件（如疼痛、病理性骨折、脊髓压迫和高钙血症）的药物，目前包括双膦酸盐类和RANKL抑制剂。由于骨改良药物的广泛使用，其不良反应逐渐增多并影响患者生活质量。中国医师协会乳腺癌专业委员会和中国抗癌协会国际医疗专业委员会组织相关专家基于循证医学，聚焦晚期恶性肿瘤骨转移的治疗，讨论骨改良药物不良反应的管理并形成本共识。本共识在国内首部《骨改良药物安全性管理专家共识》的基础上，增加了与骨改良药物相关的颌骨坏死的定义、文献报道的骨改良药物不良反应发生情况，并总结了近年来临床医生在实践中管理不良反应的临床经验，最终，专家组成员经讨论提出合理建议，以指导临床医生对骨改良药物进行安全性管理。
